Versantis
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Versantis was a Zurich, Switzerland-based clinical-stage biotechnology company focused on liver diseases. Its lead target was acute-on-chronic liver failure (ACLF), a rapidly progressing and potentially fatal syndrome with no FDA-approved therapies that puts an estimated 137,000 patients in US hospitals each year. Its lead asset was VS-01, a Phase 2-ready program based on liposome technology, plus a preclinical small-molecule program.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Clinical development
Versantis advanced VS-01 through Phase 1b for acute-on-chronic liver failure, with encouraging preclinical and clinical data.
- Acquired by Genfit
French biopharma Genfit agreed to buy Versantis for 40 million Swiss francs upfront (about $41.4 million), with up to 65 million Swiss francs (about $67.3 million) in additional payments tied to clinical and regulatory milestones. The share purchase agreement was signed and the acquisition completed on September 29, 2022, adding VS-01 to Genfit's ACLF franchise.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.